Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.

TY - JOUR

T1 - Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.

AU - Holst, Jens Juul

AU - Deacon, Carolyn F

N1 - Keywords: Animals; Antigens, CD26; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Great Britain; Humans; Peptide Fragments; Protease Inhibitors; Protein Precursors

PY - 2004

Y1 - 2004

N2 - Proof-of-concept for the efficacy of a glucagon-like peptide 1 (GLP-1)-based therapy of patients with type 2 diabetes was provided in 2002 by means of prolonged continuous subcutaneous infusion of native GLP-1. Since then, several long-acting analogues of GLP-1, as well as inhibitors of dipeptidyl peptidase IV, the enzyme that rapidly inactivates endogenous GLP-1, have demonstrated efficacy in long term clinical trials.

AB - Proof-of-concept for the efficacy of a glucagon-like peptide 1 (GLP-1)-based therapy of patients with type 2 diabetes was provided in 2002 by means of prolonged continuous subcutaneous infusion of native GLP-1. Since then, several long-acting analogues of GLP-1, as well as inhibitors of dipeptidyl peptidase IV, the enzyme that rapidly inactivates endogenous GLP-1, have demonstrated efficacy in long term clinical trials.

U2 - 10.1016/j.coph.2004.08.005

DO - 10.1016/j.coph.2004.08.005

M3 - Journal article

C2 - 15525549

SN - 1471-4892

VL - 4

SP - 589

EP - 596

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

IS - 6

ER -